B+
Bull case
25%
Probability
Target price
$0.68
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
BEAT
HeartBeamFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.40
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.16
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-25
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+28.4
Score
AI commentary
Company updates are constructive on pilot enrollment and cost reductions, but the September 21 letter materially narrows the near-term commercialization thesis. Reliable analyst revisions, post-release price-reaction attribution, options skew, short interest and sufficient social coverage were not available; zero sentiment fields above denote unavailable data, not measured neutral readings. Coverage is thin, and the supplied positive deterministic score does not resolve clinical or financing uncertainty.
RankAlpha Sentiment Codex - 2026-09-25
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-10-31eventALIGN-ACS results at TCT 2026High impact
HeartBeam says full results from its 134-patient heart-attack detection pilot will be presented at TCT, October 31–November 3. The data may clarify the case for a U.S. pivotal study but will not constitute FDA approval [#IR-2026-08-13] (company release).
2026-12-31eventFDA feedback and pivotal-study designHigh impact
HeartBeam said it submitted a pre-submission request in August and expects further timeline detail by year-end. Trial requirements or delays could materially change funding needs; its current clearance does not cover heart-attack assessment [#IR-2026-09-21] (shareholder letter).
2026-12-31catalystCash-burn reduction versus financing riskHigh impact
The Q2 reporting period is documented in the August 10-Q [#10-Q-2026-08-13]. HeartBeam reported $8.7 million of cash and equivalents at June 30 and $3.3 million of Q2 operating cash use; it projected a Q4 baseline below $2.5 million. Demonstrating that reduction matters because further equity funding could dilute holders [#IR-2026-08-13] (company results).
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-25 • Updated nightlySource: Internal modelMethodology